ASTHMA MODELS

Holistic approaches to your preclinical asthma studies.

The main challenge faced when designing asthma studies is finding models that cover all aspects of the disease pathophysiology. They must encompass both the sensitization and the challenge phase which provides all necessary data on both the onset and development of the condition. The causative agents of asthma are too many to list, but a few provide study models with the holistic approach that your pipelines need. These include the OVA-induced asthma in mice and rats model, and the HDM-induced asthma in mice and rats model, both of which are available at PharmaLegacy. Contact us, and let’s start collecting the data your asthma pipeline needs.

Contact Us
Asthma

MODELS / SERVICES

Model Characteristics:

·         Migration of inflammatory cells, in particular eosinophils and lymphocytes, into the lung tissue;

·         Vasodilation and degranulation of mast cells;

·         Release of additional inflammatory mediators by Th2 lymphocytes, such as IL-4, IL-5 and IL-13, which play important roles in the pathogenesis of asthma;

·         Destruction of epithelial layer.

Measurement of Pharmacology and Inflammatory Responses:

·         Total cell numbers and differential cell counts in broncho-alveolar lavage fluid (BALF);

·         Lung function test (airway hyper-responsiveness, Penh method);

·         Serum levels of total and OVA-specific IgE;

·         IL-4, IL-5 and IL-13 levels in BALF and lung tissue (ELISA);

·         IL-4, IL-5 and IL-13 mRNA levels in lung tissue (qRT-PCR);

·         Histopathology analysis of infiltration.

Case: OVA-induced Asthma in BALB/c Mice

Effect of Dexamethasone on OVA-Induced Asthma in BALB/c Mice

Effect of Dexamethasone on Cytokines in Lung and BALF in OVA Induced Asthma Mice

Effect of Dexamethasone on Cytokines mRNA in Lung of OVA Induced Asthma Mice


Representative HE staining of lung sections

Evaluation of Therapeutic Profile and Potentials of The Candidate Compounds:

PharmaLegacy has reproduced the airway eosinophilia, pulmonary inflammation, and elevated IgE levels found during asthma. This includes the expertise of asthma inflammation research with fully validated ovalbumin (OVA)-induced allergic asthma models in both BALB/c mice and Brown- Norway / Wistar rats. The established experience of PharmaLegacy can efficiently assist our clients in potential drug candidate screening as well as proof-of-concept studies for profiling of novel reagents targeting anti-inflammatory therapies for treatment of asthma.

Model Characteristics:

·         Migration of inflammatory cells, in particular eosinophils and lymphocytes into the lung tissue;

·         Vasodilation and degranulation of mast cells;

·         Release of additional inflammatory mediators by Th2 lymphocytes, such as IL-4, IL-5 and IL-13, which play important roles in the pathogenesis of asthma.

·         Destruction of epithelial layer

Measurement of Pharmacology and Inflammatory Responses:

·         Total cell numbers and differential cell counts in broncho-alveolar lavage fluid (BALF)

·         Lung function test (airway hyper-responsiveness, Penh method)

·         Serum levels of total and OVA-specific IgE

·         IL-4, IL-5 and IL-13 levels in BALF and lung tissue (ELISA)

·         IL-4, IL-5 and IL-13 mRNA levels in lung tissue (qRT-PCR)

·         Histopathology analysis of infiltration

Case Study:

HDM-Induced Severe Asthma in BALB/c Mice

Animal:    BALB/c Mice

Material:  HDM

Experimental Design


Endpoint : % Baseline Penh on Day 27


Endpoint: Differential Cell Percentage in BALF on Day 28


Endpoint : % Baseline Penh on Day 41

Endpoint: Differential Cell Percentage in BALF on Day 42

Committed to success:

  • FDA Part 11 compliant
  • 24/7 access to PharmaLegacy representatives
  • Scientific staff with an average of over 15 years of experience in pharmacology
  • AAALAC and CNAS guidelines-adherent animal studies

Entrust your pipeline to a CRO that strives for excellence. Entrust it to PharmaLegacy.

Contact Us

We’re ready when you are.

Tell us your pharmacology challenges.